Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia

International Journal of Cardiology

Volumn 146, Issue 3, 2011, Pages 420-421

  Ueda, Shin Ichiro ^a   Miyake, Ikuyo ^b   Takata, Kazuna ^b   Shimizu, Naomi ^b   Shirotani, Katsuro ^c   Ishida, Shiro ^d   Yonemitsu, Kazuaki ^e   Maeyama, Toyoaki ^f   Saito, Fumihiko ^g   Saito, Hiroyuki ^g   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tobata Kyoritsu Hospital   (Japan)

^c Kyoritsu Clinic   (Japan)

^d Ishida Clinic   (Japan)

^e Yonemitsu Clinic   (Japan)

^f Maeyama Internal Medicine   (Japan)

^g Saito Clinic   (Japan)

Author keywords

Cardiovascular disease; Ezetimibe; MDA LDL; Oxidative stress

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SITOSTEROL;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DISEASE COURSE; DISEASE MARKER; ESSENTIAL HYPERTENSION; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 78951491762     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.082     Document Type: Article

References (13)

1. J.L. Goldstein, and M.S. Brown Molecular medicine: the cholesterol quartet Science 292 2001 1310 1312
2. A. Mertens, and P. Holvoet Oxidized LDL and HDL: antagonists in atherothrombosis FASEB J 15 2001 2073 2084
3. S. Yla-Herttuala, W. Palinski, and M.E. Rosenfeld Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man J Clin Invest 84 1989 1086 1095
4. R. Stocker, and J.F. Keaney Jr. Role of oxidative modifications in atherosclerosis Physiol Rev 84 2004 1381 1478
5. P. Holvoet, J. Vanhaecke, S. Janssens, A. Mertens, F. Van de Werf, and D. Collen Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease Circulation 98 1998 1487 1494
6. K. Tanaga, H. Bujo, and M. Inoue Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles Arterioscler Thromb Vasc Biol 22 2002 662 666
7. M. Hiki, K. Shimada, and H. Ohmura Serume level of remnant lipoprotein cholesterol and oxidized low-density-lipoprotein in patients with coronary artery disease J Cardiol 53 2009 108 116
8. N.R. Matthan, M. Pencina, and J.M. Larocque Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease J Lipid Res 50 2009 1927 1935
9. G. Assmann, P. Cullen, J. Erbey, D.R. Ramey, F. Kannenberg, and H. Schulte Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study Nutr Metab Cardiovasc Dis 16 2006 13 21
10. I. Staprans, X.M. Pan, J.H. Rapp, A.H. Moser, and K.R. Feingold Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins J Lipid Res 47 2006 2575 2580
11. K. Nakamura, T. Matsui, H. Adachi, and S. Yamagishi Involvement of angiotensin II in intestinal cholesterol absorption Pharmacol Res 61 2010 460 465
12. T. Nakamura, E. Sato, and N. Fujiwara Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner Pharmacol Res 60 2009 525 528
13. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150